Phase IIa AZD1386 in Posttraumatic and Postherpetic Neuralgia

Phase 2, randomised, double-blind trial in post-traumatic neuralgia, postherpetic neuralgia (PHN) and Neuralgia comparing AZD1386 with Placebo (2 arms). Primary endpoints: Change from baseline in NRS pain (12-hour recall), morning measurement and Change from baseline in NRS pain (12-hour recall), evening measurement. Started Jun 2009; status: terminated.